Brachial and lumbar neuropathies

J. W. Russell, Anthony John Windebank

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Sporadic acute brachial plexus neuropathy occurs in approximately 1.64/100 000 population, but may present in epidemic form. Sporadic lumbosacral plexus neuropathy is far less common and has to be distinguished from more common disorders affecting the plexus and roots such as diabetes. Early this century, when serum therapy became popular to treat or prevent prevalent infectious diseases, it became apparent that a plexopathy could follow treatment. It has thus been assumed that many of the cases are due to an autoimmune or inflammatory lesion of the plexus. A wide variety of vaccines, infections and medications seem able to precipitate the disorder. Recent work has shown that cultured lymphocytes from affected patients, but not controls, are able to mount a blastogenic response to components of cadaver brachial plexus. This response seems to be selective not only to the brachial plexus, but also to discrete components of the plexus. The recovery rate in brachial plexus neuropathy is good, being almost 90% at 3 years. Recovery with lumbosacral disease is less satisfactory. Histological material and descriptions of acute brachial plexus neuropathy are rare. There is some evidence that an inflammatory process is present, but the role of demyelination and axonal atrophy in producing the observed clinical signs, is still uncertain. Virtually nothing is known about the histological changes in lumbosacral plexus neuropathy. Treatment is mainly supportive, but important in limiting disability. Steroids may help relieve pain in the acute stages, but do not seem to alter the prognosis.

Original languageEnglish (US)
Pages (from-to)173-191
Number of pages19
JournalBailliere's Clinical Neurology
Volume3
Issue number1
StatePublished - 1994

Fingerprint

Brachial Plexus Neuropathies
Lumbosacral Plexus
Arm
Brachial Plexus
Demyelinating Diseases
Cadaver
Atrophy
Communicable Diseases
Therapeutics
Vaccines
Steroids
Lymphocytes
Pain
Infection
Serum
Population

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Brachial and lumbar neuropathies. / Russell, J. W.; Windebank, Anthony John.

In: Bailliere's Clinical Neurology, Vol. 3, No. 1, 1994, p. 173-191.

Research output: Contribution to journalArticle

Russell, J. W. ; Windebank, Anthony John. / Brachial and lumbar neuropathies. In: Bailliere's Clinical Neurology. 1994 ; Vol. 3, No. 1. pp. 173-191.
@article{53167e9905524164a9cd53966f23e286,
title = "Brachial and lumbar neuropathies",
abstract = "Sporadic acute brachial plexus neuropathy occurs in approximately 1.64/100 000 population, but may present in epidemic form. Sporadic lumbosacral plexus neuropathy is far less common and has to be distinguished from more common disorders affecting the plexus and roots such as diabetes. Early this century, when serum therapy became popular to treat or prevent prevalent infectious diseases, it became apparent that a plexopathy could follow treatment. It has thus been assumed that many of the cases are due to an autoimmune or inflammatory lesion of the plexus. A wide variety of vaccines, infections and medications seem able to precipitate the disorder. Recent work has shown that cultured lymphocytes from affected patients, but not controls, are able to mount a blastogenic response to components of cadaver brachial plexus. This response seems to be selective not only to the brachial plexus, but also to discrete components of the plexus. The recovery rate in brachial plexus neuropathy is good, being almost 90{\%} at 3 years. Recovery with lumbosacral disease is less satisfactory. Histological material and descriptions of acute brachial plexus neuropathy are rare. There is some evidence that an inflammatory process is present, but the role of demyelination and axonal atrophy in producing the observed clinical signs, is still uncertain. Virtually nothing is known about the histological changes in lumbosacral plexus neuropathy. Treatment is mainly supportive, but important in limiting disability. Steroids may help relieve pain in the acute stages, but do not seem to alter the prognosis.",
author = "Russell, {J. W.} and Windebank, {Anthony John}",
year = "1994",
language = "English (US)",
volume = "3",
pages = "173--191",
journal = "Bailliere's Clinical Neurology",
issn = "0961-0421",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - Brachial and lumbar neuropathies

AU - Russell, J. W.

AU - Windebank, Anthony John

PY - 1994

Y1 - 1994

N2 - Sporadic acute brachial plexus neuropathy occurs in approximately 1.64/100 000 population, but may present in epidemic form. Sporadic lumbosacral plexus neuropathy is far less common and has to be distinguished from more common disorders affecting the plexus and roots such as diabetes. Early this century, when serum therapy became popular to treat or prevent prevalent infectious diseases, it became apparent that a plexopathy could follow treatment. It has thus been assumed that many of the cases are due to an autoimmune or inflammatory lesion of the plexus. A wide variety of vaccines, infections and medications seem able to precipitate the disorder. Recent work has shown that cultured lymphocytes from affected patients, but not controls, are able to mount a blastogenic response to components of cadaver brachial plexus. This response seems to be selective not only to the brachial plexus, but also to discrete components of the plexus. The recovery rate in brachial plexus neuropathy is good, being almost 90% at 3 years. Recovery with lumbosacral disease is less satisfactory. Histological material and descriptions of acute brachial plexus neuropathy are rare. There is some evidence that an inflammatory process is present, but the role of demyelination and axonal atrophy in producing the observed clinical signs, is still uncertain. Virtually nothing is known about the histological changes in lumbosacral plexus neuropathy. Treatment is mainly supportive, but important in limiting disability. Steroids may help relieve pain in the acute stages, but do not seem to alter the prognosis.

AB - Sporadic acute brachial plexus neuropathy occurs in approximately 1.64/100 000 population, but may present in epidemic form. Sporadic lumbosacral plexus neuropathy is far less common and has to be distinguished from more common disorders affecting the plexus and roots such as diabetes. Early this century, when serum therapy became popular to treat or prevent prevalent infectious diseases, it became apparent that a plexopathy could follow treatment. It has thus been assumed that many of the cases are due to an autoimmune or inflammatory lesion of the plexus. A wide variety of vaccines, infections and medications seem able to precipitate the disorder. Recent work has shown that cultured lymphocytes from affected patients, but not controls, are able to mount a blastogenic response to components of cadaver brachial plexus. This response seems to be selective not only to the brachial plexus, but also to discrete components of the plexus. The recovery rate in brachial plexus neuropathy is good, being almost 90% at 3 years. Recovery with lumbosacral disease is less satisfactory. Histological material and descriptions of acute brachial plexus neuropathy are rare. There is some evidence that an inflammatory process is present, but the role of demyelination and axonal atrophy in producing the observed clinical signs, is still uncertain. Virtually nothing is known about the histological changes in lumbosacral plexus neuropathy. Treatment is mainly supportive, but important in limiting disability. Steroids may help relieve pain in the acute stages, but do not seem to alter the prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0027938817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027938817&partnerID=8YFLogxK

M3 - Article

C2 - 7921588

AN - SCOPUS:0027938817

VL - 3

SP - 173

EP - 191

JO - Bailliere's Clinical Neurology

JF - Bailliere's Clinical Neurology

SN - 0961-0421

IS - 1

ER -